openPR Logo
Press release

Ankylosing Spondylitis Therapeutics - Pipeline Review, in-Depth Study on Therapeutics Development, Assessment & Growth of Leading Key Players AbbVie Inc, Sanofi SA, Regeneron Pharmaceuticals Inc

02-07-2018 01:32 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Ankylosing Spondylitis Therapeutics - Pipeline Review,

Ankylosing spondylitis is an idiopathic disease, associated with HLA-B27, IL23R and ERAP1 genes. Usually, fewer people get affected with ankylosing spondylitis irrespective of activation of genes. Blood test, X-ray test, Magnetic Resonance Imaging (MRI) and physical investigations are some of the ways to effectively diagnose the disease. The disease begins with the inflammation in joints in the vertebrae and pelvic bones and spine. The environmental factors are believed to be the most important risk factor for increasing the incidence of the disease. The primary symptoms include back pain and stiffness.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis/report-sample

Companies have conducted clinical trials for evaluating the effectiveness and safety of the drugs. The drugs have shown promising results in treatment of the disease. For example, secukinumab from Novartis AG is in Clinical Phase III, filgotinib from Galapagos NV is in Phase II, IBI303 from Innovent Biologics (Suzhou) Co. Ltd. is in Clinical Phase III, BCD-085 from Biocad Inc. is in Clinical Phase II, certolizumab Pegol from UCB Pharma S.A. is in Clinical Phase III, ixekizumab from Eli Lilly and Company is in Clinical Phase III and brodalumab from Amgen plc is in Clinical Phase II. In April 2017, the drug filgotinib from Galapagos NV in collaboration with Gilead Science Inc., was verified by a proof-of-concept study for the treatment of cutaneous lupus erythematosus. Additionally, filgotinib is in Phase II clinical study, for the treatment of ankylosing spondylitis, Sjögren's syndrome, and psoriatic arthritis. In April 2017, Unichem Laboratories Ltd. received USFDA approval for a pain killer drug, piroxicam, for the inflammatory conditions in ankylosing spondylitis, osteoarthritis and rheumatoid arthritis such as, swelling, stiffness and joint pain.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis

Some of the companies having a pipeline of ankylosing spondylitis therapeutics include, AbbVie Inc., Sanofi SA, Centocor Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Janssen Research & Development, LLC, Novartis AG, Amgen plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp., Galapagos NV, Celgene Corporation, Shanghai Pharmaceuticals Holding Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Pfizer Inc., UCB Pharma SA, Eli Lilly and Company, Eisai Co., Ltd., Korea Otsuka Pharmaceutical Co., Ltd., Inflexxion Inc. and Johnson & Johnson Pvt. Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ankylosing Spondylitis Therapeutics - Pipeline Review, in-Depth Study on Therapeutics Development, Assessment & Growth of Leading Key Players AbbVie Inc, Sanofi SA, Regeneron Pharmaceuticals Inc here

News-ID: 935488 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Phase

Three-Phase Hybrid Inverter Market Efficient and Reliable Power Conversion Solut …
Global Three-Phase Hybrid Inverter Market Overview: The Three-Phase Hybrid Inverter market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others. In recent years, the Three-Phase Hybrid Inverter market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth
Clinical Trials by Phase (Phase I, Phase II, Phase III, Phase IV) Market Forecas …
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care. Download Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00006203/?utm_source=OpenPR&utm_medium=10379 Key Players Analysis:  IQVIA  Parexel International Corporation  Charles River Laboratories  ICON plc  SGS SA  Chiltern International Ltd  Syneos Health  PRA Health Sciences  Wuxi AppTec Inc  Pharmaceutical Product Development,
Digital Phase Shifters Market
Digital Phase Shifters Market A recently identified vacuum in the literature about the creation of digital phase shifters for modern communication systems is attempted to be filled in the book Design of Digital Phase Shifters for Multipurpose Communication Systems. By significantly reducing RF power consumption and improving noise immunity, directed beams enhance the development of new-generation mobile communication systems. In this regard, digital phase shifters in particular, which are part
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022 The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027. HIV Vaccines Market - Segmentation The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region. Antibiotics have been segmented into dicloxacillin,